Articles | March 30, 2022
Highlights included positive Phase 2b data with COMP360 from a ground-breaking treatment resistant depression (TRD) trial, highly encouraging Phase 2a proof-of-mechanism data with RL-007 in cognitive impairment associated with schizophrenia (CIAS), clinical trial initiations with PCN-101, GRX-917 and DMX-1002, and successful completion of 2 cohorts in the Introspect Digital Therapeutics… Read More
Articles | March 23, 2022
atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a webcast on Wednesday, March 30, 2022 at 8:30 a.m. ET to discuss its financial results for the fourth quarter 2021 and provide… Read More
Articles | March 21, 2022
atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conferences in March: Citi Winter Biotech Virtual Bus Tour Format: Fireside Chat – VirtualDate and Time: Tuesday, March 22nd, 11:00 a.m. ET… Read More
Articles | February 16, 2022
Leading non-profit and commercial organizations in psychedelic science united in visions to heal mental health conditions Donation is from atai Impact, the philanthropic arm of mental health company, atai Life Sciences Funds will help support the general operations of MAPS, including its Health Equity Program to increase diversity, equity and… Read More
Articles | February 15, 2022
atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conference in February. Presentation details can be found below: Aegis Conference Format: Virtual Date and Time: Thursday, February 24, 2022, 11:30… Read More
Articles | January 27, 2022
Invyxis will add proven medicinal chemistry and comprehensive biological evaluation capabilities to grow atai’s portfolio of new chemical entities (NCEs) Early focus will be on designing unique, novel compounds aimed at the serotonin 5-HT2A receptor with other central nervous system (CNS) targets to follow This new platform company is a… Read More
Articles | January 12, 2022
Enables expansion of PCN-101 clinical development to the U.S. atai plans to initiate clinical drug-drug interaction (DDI) study in early 2022 to assess pharmacokinetics of PCN-101 when used concurrently with other drugs DDI trial will complement existing Phase 2a trial in treatment-resistant depression (TRD) recently initiated in Europe atai Life… Read More
Articles | January 10, 2022
atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conference today: H.C. Wainwright BioConnect Conference (Virtual) Format: Fireside Chat Date and Time: Monday, January 10th, 2022, 2:00 p.m. ET… Read More
Articles | December 16, 2021
atai Impact’s first major initiative will support promising academics in researching the therapeutic potential of psychedelic compounds to address unmet needs in mental health The Fund aims to help unlock the mysteries of the brain, improve the treatment of mental health conditions and positively change the future of brain health… Read More
Articles | December 15, 2021
Apeiron and other key shareholders enter into voluntary lock-up agreements This voluntary lock-up extends trading restrictions by 24 months for Apeiron and 12 months for other investors Demonstrates strong ongoing confidence in atai’s diversified platform and multiple innovative programs designed to address unmet patient need in mental health atai Life… Read More